EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The pathogenic role of retinoid nuclear receptor signaling in cancer and metabolic syndromes

Mark Esposito iD, John K Amory iD, Yibin Kang iD

Journal of Experimental Medicine · 02.09.2024 · 221 (9)

DOI: 10.1084/jem.20240519 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Experimental Medicine, online erschienen am 12.08.2024. Verfasst von Mark Esposito und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Biology, Princeton University, Princeton, NJ, USA. Hauptthemen laut MEDLINE: Signal Transduction, Neoplasms, Metabolic Syndrome. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 229 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, Breast Cancer Research Foundation, Brewster Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The retinoid nuclear receptor pathway, activated by the vitamin A metabolite retinoic acid, has been extensively investigated for over a century. This study has resulted in conflicting hypotheses about how the pathway regulates health and how it should be pharmaceutically manipulated. These disagreements arise from a fundamental contradiction: retinoid agonists offer clear benefits to select patients with rare bone growth disorders, acute promyelocytic leukemia, and some dermatologic diseases, yet therapeutic retinoid pathway activation frequently causes more harm than good, both through acute metabolic dysregulation and a delayed cancer-promoting effect. In this review, we discuss controlled clinical, mechanistic, and genetic data to suggest several disease settings where inhibition of the retinoid pathway may be a compelling therapeutic strategy, such as solid cancers or metabolic syndromes, and also caution against continued testing of retinoid agonists in cancer patients. Considerable evidence suggests a central role for retinoid regulation of immunity and metabolism, with therapeutic opportunities to antagonize retinoid signaling proposed in cancer, diabetes, and obesity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Signal TransductionNeoplasmsMetabolic SyndromeHumansAnimalsReceptors, Retinoic AcidRetinoids

Substanzen

Receptors, Retinoic AcidRetinoids

Autor:innen und Institutionen

  • Department of Molecular Biology, Princeton University, Princeton, NJ, USA.
  • Kayothera, Inc , Seattle, WA, USA.
  • University of Washington , Seattle, WA, USA.
  • Ludwig Institute for Cancer Research Princeton Branch , Princeton, NJ, USA.

ORCID-Profile: Mark Esposito, John K Amory, Yibin Kang

Förderung

  • NIDDK NIH HHS
  • Breast Cancer Research Foundation
  • Brewster Foundation
  • Susan Komen Foundation
  • Eunice Kennedy Shriver National Institute of Health and Human Reproduction
  • NCI NIH HHS
  • NIH HHS
  • Ludwig Cancer Research

Zitieren

APA

Esposito, M., Amory, J. K., & Kang, Y. (2024). The pathogenic role of retinoid nuclear receptor signaling in cancer and metabolic syndromes. Journal of Experimental Medicine, 221(9). https://doi.org/10.1084/jem.20240519

Vancouver

Esposito M, Amory JK, Kang Y. The pathogenic role of retinoid nuclear receptor signaling in cancer and metabolic syndromes. Journal of Experimental Medicine. 2024;221(9). doi:10.1084/jem.20240519

BibTeX
@article{Esposito2024,
  author = {Esposito, Mark and Amory, John K and Kang, Yibin},
  title = {The pathogenic role of retinoid nuclear receptor signaling in cancer and metabolic syndromes},
  journal = {Journal of Experimental Medicine},
  year = {2024},
  volume = {221},
  number = {9},
  doi = {10.1084/jem.20240519}
}
Kostenlos starten →